IL6 and rheumatoid arthritis: For instance, a tocilizumab (IL-6 inhibitor) biosimilar was recently approved by the EMA and USFDA for the treatment of RA, with a phase III equivalence trial demonstrating comparable efficacy, safety, and immunogenicity to its originator [57].